Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Insights From a Real-World Cohort
Journal of Movement Disorders · 30.04.2026 · 19 (2) · 178-186
DOI: 10.14802/jmd.25304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Movement Disorders, erschienen am 30.04.2026. Verfasst von Clément Desjardins und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fondation Rothschild Hospital, Paris Cité University, Paris, France. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) represents a transformative therapy for advanced Parkinson’s disease (aPD), but real-world neuropsychiatric safety data remain limited, particularly in populations typically excluded from clinical trials. This study aimed to assess the frequency, clinical patterns, and predictors of neuropsychiatric and/or cognitive worsening in a real-world CSFLI-treated cohort.
Methods
We performed a retrospective observational study involving 36 consecutive aPD patients who underwent CSFLI with a six-month follow-up. Neuropsychiatric/cognitive worsening was defined as any clinically meaningful increase in the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I or the Parkinson’s Disease Questionnaire-8 (PDQ-8) cognitive/psychiatric subscores. Patients were classified as “worsening” versus “no worsening” and compared with respect to baseline characteristics. Predictors were identified using univariable and exploratory multivariable analyses.
Results
Seventeen patients (47.2%) experienced neuropsychiatric/cognitive worsening within six months. Critically, patients with prior confusion or hallucinations who were managed with baseline clozapine had significantly better outcomes: confusion history was common in 57.9% of the patients in the stable group versus 11.8% in the worsening group (p=0.006), with clozapine use corresponding to 63.2% of the patients versus 23.5% (p=0.023). Conversely, catechol-O-methyltransferase inhibitor (COMT-I) use was more frequent in the worsening group (70.6% vs. 21.1%, p=0.006). Motor outcomes remained stable at 6 months regardless of the patient’s neuropsychiatric status.
Conclusion
In a vulnerable real-world aPD population, neuropsychiatric/cognitive worsening under CSFLI was more frequent than it was in pivotal trials (47% vs. 7%–17%) but was generally mild and not associated with motor deterioration. Importantly, proactive clozapine use enabled safe CSFLI treatment in patients with psychiatric histories traditionally considered high risk. COMT-I emerged as a modifiable risk factor. These findings support broader CSFLI use with structured neuropsychiatric monitoring and proactive clozapine in selected patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Fondation Rothschild Hospital, Paris Cité University, Paris, France.
Zitieren
APA
Desjardins, C., Vaulry, H. S., Salardaine, Q., Rosset, C., Brandel, J. P., & Baille, G. (2026). Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Insights From a Real-World Cohort. Journal of Movement Disorders, 19(2), 178-186. https://doi.org/10.14802/jmd.25304
Vancouver
Desjardins C, Vaulry HS, Salardaine Q, Rosset C, Brandel JP, Baille G. Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Insights From a Real-World Cohort. Journal of Movement Disorders. 2026;19(2):178-186. doi:10.14802/jmd.25304
BibTeX
@article{Desjardins2026,
author = {Desjardins, Clément and Vaulry, Hélène de Saint and Salardaine, Quentin and Rosset, Céline and Brandel, Jean-Philippe and Baille, Guillaume},
title = {Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Insights From a Real-World Cohort},
journal = {Journal of Movement Disorders},
year = {2026},
volume = {19},
number = {2},
pages = {178--186},
doi = {10.14802/jmd.25304}
}
EUVIMED